JIANGSU AIDEA PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.3 CNY | +6.77% |
|
+1.73% | +22.30% |
| Feb. 23 | Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 09 | Aidea Pharmaceutical, Subsidiaries Get Nod to Trial Anti-HIV Drug | MT |
| Sales 2022 | 244M 33.7M | Sales 2023 | 411M 56.77M | Capitalization | 5.26B 726M |
|---|---|---|---|---|---|
| Net income 2022 | -124M -17.11M | Net income 2023 | -76M -10.49M | EV / Sales 2022 | 17 x |
| Net cash position 2022 | 278M 38.33M | Net cash position 2023 | 28.8M 3.97M | EV / Sales 2023 | 12.7 x |
| P/E ratio 2022 |
-35.1
x | P/E ratio 2023 |
-69.1
x | Employees | 421 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.57% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.77% | ||
| 1 week | +1.73% | ||
| Current month | -4.91% | ||
| 1 month | -0.71% | ||
| 3 months | +20.85% | ||
| 6 months | +33.16% | ||
| Current year | +22.30% |
1 week
13.72
15.40
1 month
13.7216.88
Current year
9.7617.40
1 year
9.6317.40
3 years
8.4327.21
5 years
8.4345.26
10 years
8.4345.26
| Managers | Title | Age | Since |
|---|---|---|---|
Jie Zhang
CEO | Chief Executive Officer | 54 | - |
Chuanhong Zhu
DFI | Director of Finance/CFO | 53 | 23-09-15 |
He Liang Fu
CHM | Chairman | 63 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
He Liang Fu
CHM | Chairman | 63 | 13-12-31 |
Guang Ji Wang
BRD | Director/Board Member | 71 | 19-05-08 |
Xiao Yan Qi
BRD | Director/Board Member | 61 | 22-03-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 15.3 | +6.77% | 5,767,705 |
| 24-04-19 | 14.33 | +1.85% | 3,916,554 |
| 24-04-18 | 14.07 | -3.50% | 4,787,611 |
| 24-04-17 | 14.58 | -0.14% | 5,398,991 |
| 24-04-16 | 14.6 | -2.93% | 7,728,470 |
End-of-day quote Shanghai S.E., April 21, 2024
More quotes
Jiangsu Aidea Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of human-source protein products. The Company is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The Company is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The Company's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The Company mainly distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +22.30% | 889M | |
| -2.68% | 85.68B | |
| +5.53% | 41.4B | |
| -24.99% | 28.22B | |
| +55.39% | 24.64B | |
| -7.19% | 16.98B | |
| -34.20% | 13.29B | |
| -17.31% | 11.66B | |
| -11.43% | 11.65B | |
| -1.80% | 8.18B |
- Stock Market
- Equities
- 688488 Stock
